A HER2-directed antibody–drug conjugate composed of a humanized anti-HER2 monoclonal antibody linked via a cleavable linker to monomethyl auristatin E (MMAE); binds ERBB2/HER2, is internalized, and releases MMAE to inhibit microtubule polymerization, causing mitotic arrest and apoptosis.
HER2-directed antibody–drug conjugate: the anti-HER2 monoclonal antibody binds ERBB2/HER2, is internalized, and via a cleavable linker releases MMAE, which inhibits microtubule polymerization, causing G2/M arrest and apoptosis (potential bystander cytotoxicity).
NO
INDIRECT
The ADC binds HER2 (not β‑tubulin), is internalized, and releases MMAE, which binds β‑tubulin to inhibit microtubule polymerization, causing G2/M arrest and apoptosis (with possible bystander killing).
A therapeutic peptide vaccine composed of PD-L1- and IDO-derived peptides designed to elicit antigen-specific CD8+ and CD4+ T-cell responses against PD-L1– and IDO-expressing cells, enhancing tumor cell killing and reducing immunosuppression.
Therapeutic vaccine comprising PD-L1- and IDO-derived peptides that elicit antigen-specific CD4+ and CD8+ T-cell responses. The induced T cells target and eliminate PD-L1– and IDO-expressing tumor and immunosuppressive cells, reducing immune suppression and restoring cytotoxic T-cell activity; Montanide ISA-51 serves as an immunologic adjuvant to enhance responses.
YES
INDIRECT
Vaccine peptides elicit PD‑L1–specific CD8+ (and CD4+) T cells; these CTLs recognize PD‑L1–derived peptides presented on MHC of PD‑L1–expressing cells and kill them via perforin/granzyme-mediated cytolysis, not by a direct drug effect.
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
YES
DIRECT
rATG contains antibodies that bind CD5 on T cells, opsonizing them for complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, with some apoptosis.
A therapeutic peptide vaccine composed of PD-L1- and IDO-derived peptides designed to elicit antigen-specific CD8+ and CD4+ T-cell responses against PD-L1– and IDO-expressing cells, enhancing tumor cell killing and reducing immunosuppression.
Therapeutic vaccine comprising PD-L1- and IDO-derived peptides that elicit antigen-specific CD4+ and CD8+ T-cell responses. The induced T cells target and eliminate PD-L1– and IDO-expressing tumor and immunosuppressive cells, reducing immune suppression and restoring cytotoxic T-cell activity; Montanide ISA-51 serves as an immunologic adjuvant to enhance responses.
YES
INDIRECT
Vaccination induces IDO1-specific CD8+/CD4+ T cells that recognize IDO1-derived peptides on MHC and kill IDO1-expressing cells via CTL mechanisms (perforin/granzyme, Fas–FasL).
Allogeneic, banked Epstein–Barr virus–specific T lymphocytes engineered to express a CD30-directed chimeric antigen receptor (CAR); binds CD30 on tumor cells to trigger T-cell activation and cytotoxicity, while the native EBV-specific TCR enables recognition of EBV antigens in EBV+ tumors, supporting persistence/expansion and dual targeting.
Allogeneic EBV-specific T lymphocytes engineered to express a CD30-directed chimeric antigen receptor. CAR engagement of CD30 on tumor cells triggers T-cell activation and cytotoxic killing of CD30+ malignant cells, while the native EBV-specific TCR enables recognition of EBV antigens in EBV+ tumors, supporting persistence/expansion and dual targeting.
YES
DIRECT
CD30-directed CAR on the infused T cells binds CD30 on target cells, activating T-cell cytotoxicity (perforin/granzyme and Fas–FasL) to kill CD30+ cells.